Prostate Cancer Patients Undergoing Radical Prostatectomy
8
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
PSMA-Targeted Intraoperative Fluorescent Imaging Agents (DGPR1008): Validation Across Different Time Windows
Limited Versus Extended Lymph Node Dissection During Radical Prostatectomy in Patients With Localized or Locally Advanced Prostate Cancer
Ejaculatory Behavior and Seminal Vesicle Size During Radical Prostatectomy
Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents
Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Advanced Pelvic Floor Training Program for Prostate Cancer Surgery
Prehabilitation for Prostate Cancer Surgery